NeuBase Therapeutics, Inc.NBSE
Market cap
$1.41M
P/E ratio
| 2011/09 | 2012/09 | 2013/09 | 2014/09 | 2015/09 | 2016/09 | 2017/09 | 2018/09 | 2019/09 | 2020/09 | 2021/09 | 2022/09 | |
| Stock-based compensation | 679,301 | 1 | 2 | 2 | 4 | 3 | 1 | 877,751 | 10 | 5 | 4 | 3 |
| Cash from operations | -1,004,527 | -1,753,829 | -2,689,687 | -5,360,132 | -10,692,985 | -15,985,889 | -19,290,972 | -9,492,423 | -2,845,488 | -10,710,071 | -18,873,684 | -29,011,966 |
| Capital expenditures | -25,018 | -58,421 | -58,421 | - | -184,951 | -14,510 | -4,833 | - | -455,200 | -716,820 | -1,438,415 | -471,711 |
| Cash from investing | 163,482 | 130,079 | 130,079 | -3,514,869 | -284,951 | -14,510 | 88,452 | 528,038 | -685,225 | -716,820 | -2,563,467 | -471,741 |
| Repurchases of common stock | - | - | - | - | - | - | - | - | 14 | - | - | - |
| Cash from financing | 3 | 7 | 12 | 17 | 26 | -150,034 | 19 | -86,264 | 14 | 33 | 42 | -257,017 |
| Free cash flow | - | - |